Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

Fig. 5

Effect of Andro on p300 HAT and acetylation of NF-κB in human breast cancer cells. a The HAT activities of human breast cancer cells were was measured. b MDA-MB-231 cells were cultured with indicated dose of Andro for 24 h. HAT activity was then determined. (*P < 0.05, **P < 0.01, Andro treatment vs vehicle control groups). c MDA-MB-231 cells were transfected with a p300 plasmid for 24 h, and then treated with Andro or C646 (p300 selective inhibitor) for 24 h. HAT activity was further determined. d The MDA-MB-231 cells were transfected with p300 plasmid for 24 h and then treated with Andro for 24 h. Nuclear extracts were prepared and p50 was immunoprecipitated with a p50 antibody. Acetylated p50 (Actyl-p50) d was analyzed by Western blots using an acetyl-lysine antibody. The binding of p50 to a biotinylated COX-2 promoter probe (e) and chromatin structure (f) were detected by streptavidin-agarose pulldown and ChIP assay, respectively. (##p < 0.01, p300 plasmid group vs control group, *P < 0.05, **P < 0.01, Andro treatment vs p300 plasmid groups)

Back to article page